Preclinical studies of the falnidamol as a highly potent and specific active ABCB1 transporter inhibitor

Preclinical studies of the falnidamol as a highly potent and specific active ABCB1 transporter inhibitor

Abstract Background ABCB1 overexpression is a key factor in causing multidrug resistance (MDR). As a result, it is crucial to discover effective medications against ABCB1 to overcome MDR. Falnidamol, a tyrosine kinase inhibitor (TKI) targeting the epidermal growth factor receptor (EGFR), is currentl...

Full description

Saved in:
Bibliographic Details
Main Authors: Baojie Liu, Yongzheng Lu, Ruihui Lin, Junbao Xu, Zilin Shang, Xinyu Hou, Xulong Shao, Zhifang Pan, Tao Yu, Weiguo Feng
Format: Article
Language:English
Published: BMC 2025-01-01
Series:BMC Cancer
Subjects:
Falnidamol
ABCB1
Multidrug resistance
Reversal effect
Cancer
Online Access:https://doi.org/10.1186/s12885-024-13371-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-024-13371-7

Similar Items